Overview

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Status:
Completed
Trial end date:
2017-05-15
Target enrollment:
Participant gender:
Summary
To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Mineralocorticoid Receptor Antagonists